The insider buying is a strong conviction signal from management, but the $50M PIPE overhang is likely to dominate near-term price action. Traders should watch for the PIPE pricing and any further insider buying at lower levels. The stock's history of severe post-filing drawdowns (-20% T+20) suggests caution despite the bullish insider cluster. A potential catalyst is the next QRX003 data readout, but the dilution risk is the primary driver.
Price Chart
Executive Summary
Three insiders at Quoin Pharmaceuticals (CEO, CFO, and a Director) made open-market purchases totaling $180K at $4.88/share on August 31, 2026, just 4 days after the company announced a $50M dilutive PIPE and positive interim Phase 2/3 data for QRX003. The insider buying is a strong signal of confidence in the clinical data and cash runway, but the massive dilution from the PIPE and the stock's history of severe post-filing drawdowns (-20% avg T+20) create a highly conflicted risk/reward profile. The cluster is a bullish signal on fundamentals, but the structural overhang from the offering is bearish for near-term price action.
Key Financial Metrics
Key Facts
- CEO Michael Myers purchased 20,490 shares at $4.88 for ~$100K in an open-market transaction on Aug 31, 2026.
- CFO Sally Lawlor purchased 10,244 shares at $4.88 for ~$50K in an open-market transaction on Aug 31, 2026.
- Director Anthony Culverwell purchased 6,146 shares at $4.88 for ~$30K in an open-market transaction on Aug 31, 2026.
- The $180K in open-market purchases represents ~1.5% of QNRX's $12M market cap, a highly material cluster.
- The insider buying occurred 4 days after a $50M PIPE offering (Aug 28, 2026) that is highly dilutive to existing shareholders.
- The PIPE was announced alongside positive interim Phase 2/3 data for QRX003 in Netherton Syndrome, but from only 6 patients.
- The stock has a poor historical track record: avg -20% T+20 return across prior reports on this ticker.
- Two directors (Langer and Culverwell) also received non-cash stock grants of ~$339K total on Aug 27, 2026, which are not market signals.
Financial Impact
Insider open-market purchases of $180K represent ~1.5% of the $12M market cap, a highly material cluster. The $50M PIPE offering will massively dilute existing shareholders.
Risk Factors
- Massive dilution from the $50M PIPE offering will pressure the stock price.
- The clinical data is from only 6 patients and may not replicate in larger trials.
- The stock has a history of severe post-filing drawdowns, with avg -20% T+20 return.
- The company has a $12M market cap and is pre-revenue, making it highly speculative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-QNRX-1788313260347 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 12, 2026 6d ago | ANALYST-UPGRADE | $4.36 $4.15 | ▼ −4.82% | ▼ −4.80% | $3.90 (−10.55%) |
Sep 2, 2026 6w ago | Insider Cluster | $6.74 $7.87 | ▲ +16.77% | ▲ +15.72% | $3.90 (−42.14%) |
Aug 28, 2026 7w ago | 8-K | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▼ −1.63% | ▼ −1.93% | $3.90 (+36.27%) |
Aug 28, 2026 7w ago | Press Release | $6.12 $6.22 | ▲ +1.63% | ▲ +1.93% | $3.90 (−36.27%) |
Aug 20, 2026 8w ago | 8-K | $5.57 $5.42 | ▼ −2.69% | ▼ −2.40% | $3.90 (−29.98%) |
Aug 7, 2026 10w ago | Press Release | $4.79 $5.36 | ▲ +11.90% | ▲ +11.93% | $3.90 (−18.58%) |
Jun 23, 2026 16w ago | 8-K | $3.83 $4.20 | ▲ +9.66% | ▲ +9.52% | $3.90 (+1.83%) |
May 7, 2026 23w ago | Press Release | $6.37 $5.93 | ▼ −6.91% | ▼ −7.74% | $3.90 (−38.78%) |
May 5, 2026 23w ago | ANALYST-UPGRADE | $6.31 $6.43 | ▲ +1.90% | ▲ +0.52% | $3.90 (−38.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access